Vascular pleiosynergy - Does it really work?

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cardiovascular risk increases exponentially by multiple risk factors. Similarly, by simultaneously treating these risk factors the therapeutic benefit can be multiplied. It is also relevant that some drugs exert extra benefit by acting beyond their main effect. A wide range of pleiotropic effects have been reported among lipid lowering statins and third-generation calcium channel blockers. These include an increase of endothelial nitric oxide (NO) production, inhibition of free radical formation and reduction of migration and proliferation of smooth muscle cells independently from the main therapeutic effect of these drugs. Favorable "therapeutic cross effects" due to pleiotropic mechanisms can be defined as pleiosynergy.

Original languageEnglish
Pages (from-to)302-304
Number of pages3
JournalCurrent Vascular Pharmacology
Volume5
Issue number4
DOIs
Publication statusPublished - Oct 2007

Fingerprint

Therapeutic Uses
Blood Vessels
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Calcium Channel Blockers
Pharmaceutical Preparations
Free Radicals
Smooth Muscle Myocytes
Nitric Oxide
Lipids
Therapeutics

Keywords

  • Amlodipine
  • Pleiotropic
  • Statin
  • Synergy
  • Vascular effect

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Vascular pleiosynergy - Does it really work? / Császár, A.

In: Current Vascular Pharmacology, Vol. 5, No. 4, 10.2007, p. 302-304.

Research output: Contribution to journalArticle

@article{cac26ac844e541388cf000eaf51c0a0b,
title = "Vascular pleiosynergy - Does it really work?",
abstract = "Cardiovascular risk increases exponentially by multiple risk factors. Similarly, by simultaneously treating these risk factors the therapeutic benefit can be multiplied. It is also relevant that some drugs exert extra benefit by acting beyond their main effect. A wide range of pleiotropic effects have been reported among lipid lowering statins and third-generation calcium channel blockers. These include an increase of endothelial nitric oxide (NO) production, inhibition of free radical formation and reduction of migration and proliferation of smooth muscle cells independently from the main therapeutic effect of these drugs. Favorable {"}therapeutic cross effects{"} due to pleiotropic mechanisms can be defined as pleiosynergy.",
keywords = "Amlodipine, Pleiotropic, Statin, Synergy, Vascular effect",
author = "A. Cs{\'a}sz{\'a}r",
year = "2007",
month = "10",
doi = "10.2174/157016107782023352",
language = "English",
volume = "5",
pages = "302--304",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Vascular pleiosynergy - Does it really work?

AU - Császár, A.

PY - 2007/10

Y1 - 2007/10

N2 - Cardiovascular risk increases exponentially by multiple risk factors. Similarly, by simultaneously treating these risk factors the therapeutic benefit can be multiplied. It is also relevant that some drugs exert extra benefit by acting beyond their main effect. A wide range of pleiotropic effects have been reported among lipid lowering statins and third-generation calcium channel blockers. These include an increase of endothelial nitric oxide (NO) production, inhibition of free radical formation and reduction of migration and proliferation of smooth muscle cells independently from the main therapeutic effect of these drugs. Favorable "therapeutic cross effects" due to pleiotropic mechanisms can be defined as pleiosynergy.

AB - Cardiovascular risk increases exponentially by multiple risk factors. Similarly, by simultaneously treating these risk factors the therapeutic benefit can be multiplied. It is also relevant that some drugs exert extra benefit by acting beyond their main effect. A wide range of pleiotropic effects have been reported among lipid lowering statins and third-generation calcium channel blockers. These include an increase of endothelial nitric oxide (NO) production, inhibition of free radical formation and reduction of migration and proliferation of smooth muscle cells independently from the main therapeutic effect of these drugs. Favorable "therapeutic cross effects" due to pleiotropic mechanisms can be defined as pleiosynergy.

KW - Amlodipine

KW - Pleiotropic

KW - Statin

KW - Synergy

KW - Vascular effect

UR - http://www.scopus.com/inward/record.url?scp=38449106350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449106350&partnerID=8YFLogxK

U2 - 10.2174/157016107782023352

DO - 10.2174/157016107782023352

M3 - Article

C2 - 17979796

AN - SCOPUS:38449106350

VL - 5

SP - 302

EP - 304

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 4

ER -